Author Correction: The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease (Scientific Reports, (2017), 7, 1, (17193), 10.1038/s41598-017-17370-6);The Transcriptomic Signature of Disease Development and Progression of Nonalcoholic Fatty Liver Disease

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Cazanave, Sophie ^a   Podtelezhnikov, Alexei ^b   Jensen, Kristian ^b   Seneshaw, Mulugeta ^a   Kumar, DIvya P ^a   Min, Hae Ki ^a   Santhekadur, Prasanna K ^a   Banini, Bubu ^a   Mauro, Adolfo Gabriele ^c   Oseini, Abdul M ^a   Vincent, Robert ^a   Tanis, Keith Q ^b   Webber, Andrea L ^b   Wang, Liangsu ^b   Bedossa, Pierre ^d   Mirshahi, Faridoddin ^a   Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE EXACERBATION; GENE EXPRESSION PROFILING; GENETICS; LIVER CIRRHOSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION;

EID: 85037618929     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-020-65506-y     Document Type: Erratum

References (52)

1. Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686-690 (2013).
2. Pais, R. et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. Journal of Hepatology 59, 550-556 (2013).
3. Schattenberg, J. M. & Schuppan, D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr. Opin. Lipidol. 22, 479-88 (2011).
4. Pacana, T. & Sanyal, A. J. Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000Prime Rep. 7, 28 (2015).
5. Peverill, W., Powell, L. W. & Skoien, R. Evolving concepts in the pathogenesis of NASH: Beyond steatosis and inflammation. International Journal of Molecular Sciences 15, 8591-8638 (2014).
6. Caligiuri, A., Gentilini, A. & Marra, F. Molecular pathogenesis of NASH. International Journal of Molecular Sciences 17 (2016).
7. Roychowdhury, S. & Chinnaiyan, A. M. Translating cancer genomes and transcriptomes for precision oncology. CA. Cancer J. Clin. 66, 75-88 (2016).
8. Kirpich, I. A. et al. Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J. Nutr. Biochem. 22, 38-45 (2011).
9. Roberts, M. D. et al. Western diet-induced hepatic steatosis and alterations in the liver transcriptome in adult Brown-Norway rats. BMC Gastroenterol. 15, 151 (2015).
10. Dorn, C. et al. Increased expression of c-Jun in nonalcoholic fatty liver disease. Lab. Investig. 94, 394-408 (2014).
11. Teufel, A. et al. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues from Patients. Gastroenterology 151, 513-525.e0 (2016).
12. Hill-Baskin, A. E. et al. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum. Mol. Genet. 18, 2975-2988 (2009).
13. Asgharpour, A. et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J. Hepatol. 65 (2016).
14. Lambert, G. et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278, 2563-2570 (2003).
15. Engelking, L. J. et al. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulinstimulated lipogenesis. J. Clin. Invest. 113, 1168-1175 (2004).
16. Yau, S. W., Azar, W. J., Sabin, M. A., Werther, G. A. & Russo, V. C. IGFBP-2-taking the lead in growth, metabolism and cancer. J. Cell Commun. Signal. 9, 125-142 (2015).
17. Cazanave, S. C. & Gores, G. J. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin. Lipidol. 5 (2010).
18. Takahashi, Y. & Fukusato, T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 20, 15539-15548 (2014).
19. Yang, D. et al. Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood 102, 3396-3403 (2003).
20. Almeda-Valdes, P., Aguilar Olivos, N. E., Barranco-Fragoso, B., Uribe, M. & Méndez-Sánchez, N. The Role of Dendritic Cells in Fibrosis Progression in Nonalcoholic Fatty Liver Disease. Biomed Res. Int. 2015, 1-7 (2015).
21. He, L., Deng, T. & Luo, H. S. Alcohol dehydrogenase 1C (ADH1C) gene polymorphism and alcoholic liver cirrhosis risk: A meta analysis. Int. J. Clin. Exp. Med. 8, 11117-11124 (2015).
22. Iredale, J. P., Thompson, A. & Henderson, N. C. Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation. Biochim. Biophys. Acta-Mol. Basis Dis. 1832, 876-883 (2013).
23. Liu, X., Gong, H. & Huang, K. Oncogenic role of kinesin proteins and targeting kinesin therapy. Cancer Science 104, 651-656 (2013).
24. Zhang, W. et al. Annexin A2 Promotes the Migration and Invasion of Human Hepatocellular Carcinoma Cells In Vitro by Regulating the Shedding of CD147-Harboring Microvesicles from Tumor Cells. PLoS One 8 (2013).
25. Maric, G., Rose, A. A. N., Annis, M. G. & Siegel, P. M. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. OncoTargets and Therapy 6, 839-852 (2013).
26. Ahmed, H. & Alsadek, D. M. M. Galectin-3 as a potential target to prevent cancer metastasis. Clin. Med. Insights Oncol. 9, 113-121 (2015).
27. Chen, J. et al. The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway. Gut gutjnl-2015-310625 https://doi.org/10.1136/gutjnl-2015-310625 (2016).
28. Sun, X. et al. Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma. BMC Cancer 15, 961 (2015).
29. Amelio, I., Cutruzzolá, F., Antonov, A., Agostini, M. & Melino, G. Serine and glycine metabolism in cancer. Trends in Biochemical Sciences 39, 191-198 (2014).
30. Montorsi, M. et al. Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 54, 2040-2044 (2007).
31. Mok, W. C., Wasser, S., Tan, T. & Lim, S. G. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma. World J. Gastroenterol. {WJG} 18, 3527-3536 (2012).
32. Wu, W. et al. CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer. J. Transl. Med. 11, 142 (2013).
33. Itzel, T. et al. Translating bioinformatics in oncology: Guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis. Bioinformatics 31, 216-224 (2015).
34. Qiu, D.-M. et al. The expression of beclin-1, an autophagic gene, in hepatocellular carcinoma associated with clinical pathological and prognostic significance. BMC Cancer 14, 327 (2014).
35. Wu, L. et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414, 457-462 (2001).
36. Salmanidis, M. et al. Hoxb8 regulates expression of microRNAs to control cell death and differentiation. Cell Death Differ. 20, 1370-80 (2013).
37. Adams, L. A. & Angulo, P. Recent concepts in non-alcoholic fatty liver disease. Diabet. Med. 22, 1129-1133 (2005).
38. Fabbrini, E., Sullivan, S. & Klein, S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 51, 679-689 (2010).
39. Sanyal, A. J. et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183-92 (2001).
40. Koliaki, C. et al. Adaptation of Hepatic Mitochondrial Function in Humans with Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis. Cell Metab. 21, 739-746 (2015).
41. Alkhouri, N., Carter-Kent, C. & Feldstein, A. E. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev. Gastroenterol. Hepatol. 5, 201-12 (2011).
42. Puri, P. et al. Activation and Dysregulation of the Unfolded Protein Response in Nonalcoholic Fatty Liver Disease. Gastroenterology 134, 568-576 (2008).
43. Amir, M. & Czaja, M. J. Autophagy in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5, 159-66 (2011).
44. Baratta, F. et al. Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. EBioMedicine 2, 750-754 (2015).
45. Cazanave, S. C. et al. Degradation of Keap1 activates BH3-only proteins Bim and PUMA during hepatocyte lipoapoptosis. Cell Death Differ. 21 (2014).
46. Cazanave, S. C. et al. CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am. J. Physiol.-Gastrointest. Liver Physiol. 299 (2010).
47. Farrell, G. C., Van Rooyen, D., Gan, L. & Chitturi, S. NASH is an inflammatory disorder: Pathogenic, prognostic and therapeutic implications. Gut and Liver 6, 149-171 (2012).
48. Syn, W.-K. et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 51, 1998-2007 (2010).
49. Guy, C. D. et al. NIH Public Access Injury and Fibrosis in Human Nonalcoholic Fatty Liver Disease. 55, 1711-1721 (2013).
50. Cheung, O. et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48, 1810-1820 (2008).
51. Charlton, M. et al. Fast food diet mouse: Novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am. J. Physiol.-Gastrointest. Liver Physiol. 301 (2011).
52. Min, H.-K. et al. Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease. Cell Metab. 15, 665-674 (2012).